Indu Lal

1.2k total citations · 1 hit paper
14 papers, 787 citations indexed

About

Indu Lal is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Indu Lal has authored 14 papers receiving a total of 787 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 9 papers in Hematology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Indu Lal's work include Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Myeloid Leukemia Research (5 papers). Indu Lal is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Myeloid Leukemia Research (5 papers). Indu Lal collaborates with scholars based in United States, United Kingdom and Spain. Indu Lal's co-authors include Aaron C. Logan, Edmund K. Waller, Corey Cutler, Mukta Arora, David B. Miklos, Samantha Jaglowski, Lori Styles, Madan Jagasia, Ryotaro Nakamura and Mary E.D. Flowers and has published in prestigious journals such as Blood, Leukemia and Biology of Blood and Marrow Transplantation.

In The Last Decade

Indu Lal

14 papers receiving 776 citations

Hit Papers

Long-term efficacy and safety of first-line ibrutinib tre... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
    2019 312 citations Jan A. Burger, Paul M. Barr et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Indu Lal United States 6 518 372 338 290 119 14 787
Małgorzata Wach Poland 11 573 1.1× 221 0.6× 448 1.3× 199 0.7× 118 1.0× 35 695
A. M. Liberati Italy 11 480 0.9× 201 0.5× 363 1.1× 158 0.5× 127 1.1× 20 689
Andrew Lipsky United States 8 566 1.1× 203 0.5× 403 1.2× 260 0.9× 103 0.9× 23 694
Saad M. B. Rassam United Kingdom 8 495 1.0× 142 0.4× 456 1.3× 285 1.0× 138 1.2× 15 686
Paul Moreton United Kingdom 12 712 1.4× 160 0.4× 649 1.9× 425 1.5× 104 0.9× 21 872
Carmen Pedro Spain 15 314 0.6× 392 1.1× 413 1.2× 126 0.4× 301 2.5× 27 885
Myriam Mendila Germany 9 778 1.5× 163 0.4× 752 2.2× 390 1.3× 148 1.2× 16 947
F Gomis Spain 16 479 0.9× 475 1.3× 435 1.3× 250 0.9× 86 0.7× 34 970
Lyndah Dreiling United States 16 408 0.8× 217 0.6× 303 0.9× 143 0.5× 464 3.9× 50 932
Gerhard Postner Austria 7 354 0.7× 109 0.3× 324 1.0× 127 0.4× 61 0.5× 8 613

Countries citing papers authored by Indu Lal

Since Specialization
Citations

This map shows the geographic impact of Indu Lal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Indu Lal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Indu Lal more than expected).

Fields of papers citing papers by Indu Lal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Indu Lal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Indu Lal. The network helps show where Indu Lal may publish in the future.

Co-authorship network of co-authors of Indu Lal

This figure shows the co-authorship network connecting the top 25 collaborators of Indu Lal. A scholar is included among the top collaborators of Indu Lal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Indu Lal. Indu Lal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Daver, Naval, Paresh Vyas, Suman Kambhampati, et al.. (2022). AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results. Clinical Lymphoma Myeloma & Leukemia. 22. S253–S254. 5 indexed citations
2.
Sallman, David A., Monzr M. Al Malki, Adam Asch, et al.. (2022). MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results. Clinical Lymphoma Myeloma & Leukemia. 22. S314–S315. 2 indexed citations
3.
Sallman, David A., Monzr M. Al Malki, Adam Asch, et al.. (2022). Oral Abstract: MDS-445 Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results. Clinical Lymphoma Myeloma & Leukemia. 22. S115–S115. 1 indexed citations
4.
Daver, Naval, Paresh Vyas, Suman Kambhampati, et al.. (2022). Poster: AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results. Clinical Lymphoma Myeloma & Leukemia. 22. S126–S126. 1 indexed citations
5.
6.
Sallman, David A., Monzr M. Al Malki, Adam Asch, et al.. (2022). Poster: MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results. Clinical Lymphoma Myeloma & Leukemia. 22. S151–S151. 1 indexed citations
7.
Blum, Lisa K., Thomas J. Kipps, Jan A. Burger, et al.. (2020). Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leukemia Research. 97. 106432–106432. 57 indexed citations
8.
9.
Waller, Edmund K., David B. Miklos, Corey Cutler, et al.. (2019). Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biology of Blood and Marrow Transplantation. 25(10). 2002–2007. 66 indexed citations
10.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2019). Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 34(3). 787–798. 312 indexed citations breakdown →
11.
Tedeschi, Alessandra, Jan A. Burger, Paul M. Barr, et al.. (2019). S107 FIVE‐YEAR FOLLOW‐UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. HemaSphere. 3(S1). 5–6. 1 indexed citations
12.
Cutler, Corey, Samantha Jaglowski, Mukta Arora, et al.. (2018). Ibrutinib for Chronic Graft-Versus-Host Disease: A Safety and Pharmacokinetic Analysis in Patients Treated with Concomitant Antifungal CYP3A Inhibitors or Immunosuppressants. Biology of Blood and Marrow Transplantation. 24(3). S186–S187. 1 indexed citations
13.
Miklos, David B., Corey Cutler, Mukta Arora, et al.. (2017). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 130(21). 2243–2250. 312 indexed citations
14.
Miklos, David B., Corey Cutler, Mukta Arora, et al.. (2016). Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. Blood. 128(22). LBA–3. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Małgorzata Wach Breakdown of academic impact, for papers by A. M. Liberati Breakdown of academic impact, for papers by Andrew Lipsky Breakdown of academic impact, for papers by Saad M. B. Rassam Breakdown of academic impact, for papers by Paul Moreton Breakdown of academic impact, for papers by Carmen Pedro Breakdown of academic impact, for papers by Myriam Mendila Breakdown of academic impact, for papers by F Gomis Breakdown of academic impact, for papers by Lyndah Dreiling Breakdown of academic impact, for papers by Gerhard Postner
Rankless by CCL
2026